VADS
TrilynX (Debio 1143-SCCHN-301)
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
Paris
CHRISTOPHE LE TOURNEAU